BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38562709)

  • 1. The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons.
    Jones-Tabah J; He K; Senkevich K; Karpilovsky N; Deyab G; Cousineau Y; Nikanorova D; Goldsmith T; Del-Cid Pellitero E; Chen CX; Luo W; You Z; Abdian N; Pietrantonio I; Goiran T; Ahmad J; Ruskey JA; Asayesh F; Spiegelman D; Waters C; Monchi O; Dauvilliers Y; Dupre N; Miliukhina I; Timofeeva A; Emelyanov A; Pchelina S; Greenbaum L; HassinBaer S; Alcalay RN; Milnerwood A; Durcan TM; Gan-Or Z; Fon EA
    Res Sq; 2024 Mar; ():. PubMed ID: 38562709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
    Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
    Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models.
    Drobny A; Boros FA; Balta D; Prieto Huarcaya S; Caylioglu D; Qazi N; Vandrey J; Schneider Y; Dobert JP; Pitcairn C; Mazzulli JR; Zunke F
    Transl Neurodegener; 2023 Jun; 12(1):31. PubMed ID: 37312133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
    Blauwendraat C; Reed X; Krohn L; Heilbron K; Bandres-Ciga S; Tan M; Gibbs JR; Hernandez DG; Kumaran R; Langston R; Bonet-Ponce L; Alcalay RN; Hassin-Baer S; Greenbaum L; Iwaki H; Leonard HL; Grenn FP; Ruskey JA; Sabir M; Ahmed S; Makarious MB; Pihlstrøm L; Toft M; van Hilten JJ; Marinus J; Schulte C; Brockmann K; Sharma M; Siitonen A; Majamaa K; Eerola-Rautio J; Tienari PJ; ; Pantelyat A; Hillis AE; Dawson TM; Rosenthal LS; Albert MS; Resnick SM; Ferrucci L; Morris CM; Pletnikova O; Troncoso J; Grosset D; Lesage S; Corvol JC; Brice A; Noyce AJ; Masliah E; Wood N; Hardy J; Shulman LM; Jankovic J; Shulman JM; Heutink P; Gasser T; Cannon P; Scholz SW; Morris H; Cookson MR; Nalls MA; Gan-Or Z; Singleton AB
    Brain; 2020 Jan; 143(1):234-248. PubMed ID: 31755958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells.
    Gao J; Perera G; Bhadbhade M; Halliday GM; Dzamko N
    J Biol Chem; 2019 Sep; 294(39):14241-14256. PubMed ID: 31375560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
    Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
    Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.
    Aflaki E; Stubblefield BK; McGlinchey RP; McMahon B; Ory DS; Sidransky E
    Neurobiol Dis; 2020 Feb; 134():104647. PubMed ID: 31669751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.
    McGlinchey RP; Lee JC
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9322-7. PubMed ID: 26170293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
    Jinn S; Drolet RE; Cramer PE; Wong AH; Toolan DM; Gretzula CA; Voleti B; Vassileva G; Disa J; Tadin-Strapps M; Stone DJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2389-2394. PubMed ID: 28193887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
    Gegg ME; Verona G; Schapira AHV
    Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.